Active heart rate measures a person’s heart activity during exercise. People can use heart rate zones to optimize workouts by ensuring that the heart rate stays within the ideal range. A person ...

Health Canada has approved Altuviiio (efanesoctocog alfa) to treat children, adolescents, and adults with hemophilia A, with the aim of preventing and controlling bleeds, including those occurring ...

Hemophilia A is a disorder that leads to nosebleeds ... cautious about bleeding risks and follow up with your needed treatments. You also need to stay active to build muscle strength and balance, ...

The main treatments used in hemophilia A and B are factor replacement therapies that contain a working version of the missing clotting factor. Such treatments can be given to patients on demand, to ...

The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or B, with or without inhibitors. Qfitlia offers less frequent administration ...

Qfitlia is the first FDA-approved antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce bleeding episodes in patients over 12 years of age with hemophilia A or B. The ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless of the presence of neutralizing antibodies against clotting factor VIII or ...

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia approved as the first therapy in the US to treat hemophilia A or B with ...

To tackle this challenge, a novel deep active convolutional transfer learning network (DACTLN), which can align the marginal as well as conditional distributions between the SD and TD and achieve ...

The U.S. Food and Drug Administration (FDA) has approved Qfitlia, a groundbreaking hemophilia treatment by French pharmaceutical giant Sanofi (NASDAQ: SNY).Designed for patients aged 12 and older ...

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent ...

Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or B With or Without Inhibitors – Alnylam Pharmaceuticals, Inc ...